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Background:  There  is  an  implied  perception  that  little  scientiﬁc  information  on  irritable  bowel
syndrome  (IBS)  comes  out  of  Mexico  and  Latin  America  in  the  international  medical  literature,
but the  number  and  tendencies  of  articles  from  the  region  on  IBS  are  not  known.
Aims: To  determine  the  number  and  type  of  Mexican  and  Latin  American  articles  on  IBS  pub-
lished between  1990-2015.
Methods:  A  systematic  search  of  Medline  was  carried  out  employing  the  terms  «Irritable  Bowel
Syndrome» or  its  abbreviation  (IBS).  Mexico  and  every  other  Latin  American  country  were  added
to specify  the  search.  The  articles  were  selected  if  they  were  published  in  Mexico  and/or  the
rest of  Latin  America,  if  they  were  international  papers  on  IBS  in  the  region,  or  if  they  were
written by  Mexican  and/or  Latin  American  authors.  In  addition,  the  articles  were  classiﬁed  into
the following  categories:  Review  Articles/Editorials/Letters  to  the  Editor  (REV/ED),  studies
emphasizing  aspects  of  Epidemiology/Quality  of  Life/Psychosocial  Factors  (EPI/QOL),  articles
dealing with  Diagnoses  (DX),  with  Treatment  (TX),  and  Translational/Pathophysiologic  studies
(TRANS).
Results: A  total  of  66  articles  from  Mexico  and  47  from  Latin  America  were  identiﬁed,  but  only
87.7 and  48.9%,  respectively,  ﬁt  the  selection  criteria.  Category  distribution  was:  EPI/QOL:
36.2%, REV/ED:  27.5%,  TRANS:  18.8,  TX:  10%,  and  DX:  7.5%  and  was  similar  between  Mexico Please cite this article as: Porras R, López-Colombo A, Schmulson M. Incremento en las publicaciones cientíﬁcas sobre síndrome de
ntestino irritable en México y Latinoamérica. Revista de Gastroenterología de México. 2015;80:228--235.
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and  Latin  America  (p  =  0.33).  The  year  2005  saw  an  increase  in  the  number  of  articles  in  Mexico,
with a  peak  in  2010.  The  ﬁgures  for  Latin  American  articles  remained  stable  over  the  years,
with a  peak  in  2012.
Conclusions:  A  noticeable  increase  has  been  observed  over  the  last  decade  in  the  research  con-
ducted on  IBS  in  Mexico  and  Latin  America.  Even  though  the  EPI/QOL  studies  predominate,  the
sophistication  of  research  is  reﬂected  in  the  TRANS  studies  that  are  in  third  place  of  frequency.
The information  referred  to  herein  demonstrates  maturity  in  the  ﬁeld,  making  it  possible  to
carry out  consensuses  based  on  local  data.
© 2015  Asociación  Mexicana  de  Gastroenterología.  Published  by  Masson  Doyma  México  S.A.
This is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Incremento  en  las  publicaciones  cientíﬁcas  sobre  síndrome  de  intestino  irritable  en
México  y  Latinoamérica
Resumen
Antecedentes:  En  la  literatura  internacional  se  crea  la  idea  de  que  la  información  cientíﬁca
sobre el  síndrome  de  intestino  irritable  (SII)  en  México  y  Latinoamérica  es  escasa.  Sin  embargo,
se desconoce  el  número  y  la  tendencia  de  las  publicaciones  sobre  SII  en  la  región.
Objetivo:  Determinar  el  número  y  tipo  de  publicaciones  sobre  SII  en  México  y  Latinoamérica
entre 1990-2015.
Métodos:  Búsqueda  sistemática  en  Medline  empleando  los  términos  «síndrome  de  intestino
irritable» o  su  abreviatura  (IBS)  en  inglés,  cruzándolo  con  México  y  cada  país  de  Latinoamérica.
Los artículos  se  seleccionaron  según  hubieran  sido  publicados  en  México  y/o  Latinoamérica;  pu-
blicaciones internacionales  sobre  SII  en  la  región  o  por  autores  mexicanos  y/o  latinoamericanos.
Además  se  clasiﬁcaron  en  categorías:  Revisión/Editorial/Cartas  al  Editor  (REV/ED),  Epide-
miología/Calidad  de  vida/Factores  psicosociales  (EPI/QOL),  Diagnóstico  (DX),  Tratamiento  (TX),
Traslacional/Fisiopatología  (TRAS).
Resultados:  Se  identiﬁcaron  66  publicaciones  de  México  y  47  de  Latinoamérica  pero  solo  un
87.7% y  un  48.9%  respectivamente  se  ajustaron  a  los  criterios  de  selección.  La  distribución  de
categorías  fue:  EPI/QOL,  36.2%;  REV/ED,  27.5%;  TRAS,  18.8;  TX,  10%;  DX,  7.5%;  similar  entre
México y  Latinoamérica  (p  =  0.33).  Las  publicaciones  se  incrementaron  a  partir  del  2005  con  un
pico en  2010  en  México,  y  se  mantuvieron  estables  a  lo  largo  de  los  an˜os  con  un  pico  en  2012
en Latinoamérica.
Conclusión:  En  la  última  década  se  observa  un  aumento  notorio  en  la  investigación  sobre  SII  en
México y  Latinoamérica.  Si  bien  predominan  los  estudios  EPI/QOL,  la  soﬁsticación  se  reﬂeja  en
los TRAS  que  ocupan  el  tercer  lugar.  Lo  anterior  demuestra  una  madurez  que  permite  realizar
consensos  basados  en  datos  locales.
© 2015  Asociación  Mexicana  de  Gastroenterología.  Publicado  por  Masson  Doyma  México  S.A.









interest,  Mexico  and  Latin  America  were  searched  sepa-Introduction
There  is  an  implied  perception  of  low  scientiﬁc  production  in
the  ﬁeld  of  functional  gastrointestinal  disorders,  and  espe-
cially  irritable  bowel  syndrome  (IBS),  in  Latin  America.  In
fact,  a  systematic  review  of  the  medical  literature  on  the
overall  prevalence  of  IBS  based  on  open  population  studies
concluded  that  there  is  a  lack  of  studies  on  the  prevalence
and  epidemiologic  characteristics  of  this  disorder,  especially
from  Central  America,  and  that  there  are  few  studies  from
South  America.1 The  review  only  identiﬁed  4 South  Ameri-
can  articles,  one  of  which  was  not  really  an  open  population
study.2 This  is  important,  given  that  IBS  has  a  reported




iBecause  our  perception  is  that  there  is  an  increase  in  IBS
esearch  in  the  region,  our  aim  was  to  carry  out  a  search  on
edline  covering  the  last  25  years.  Our  hypothesis  was  that
here  has  been  an  upsurge  in  the  number  of  articles  on  IBS
n  Mexico  and  Latin  America.
ethods
 search  was  carried  out  on  Medline  encompassing  the  time
rame  of  January  1,  1990  to  April  1,  2015.  Due  to  our  speciﬁcately.  The  terms  ‘‘Irritable  Bowel  Syndrome’’ or  ‘‘IBS’’
ere  used,  matching  them  with  ‘‘Mexico’’  or  ‘‘Latin  Amer-
ca’’.  Because  no  result  was  found  with  ‘‘Latin  America’’,

























































































































































he  search  was  repeated  with  the  names  of  each  of  the
atin  American  countries.  Two  of  the  present  authors  (RP,
S)  individually  reviewed  the  abstracts  of  each  of  the  iden-
iﬁed  articles,  and  when  necessary,  the  complete  article,  to
orroborate  that  they  met  the  selection  criteria.  Said  crite-
ia  were:  1)  Articles  on  IBS  published  in  Mexico  and/or  Latin
merica,  and/or  2)  International  articles  that  referred  to
BS  in  the  region,  and/or  3)  Articles  on  IBS  written  by  Mex-
can  and/or  Latin  American  authors.  The  same  2  authors
hen  met  to  jointly  decide  which  articles  ﬁt  the  selec-
ion  criteria;  they  excluded  articles  that  were  not  really
bout  IBS,  articles  that  were  about  IBS,  but  not  from  Mex-
co  or  Latin  America,  or  articles  that  were  not  written  by
uthors  from  the  region.  In  addition,  the  articles  were  clas-
iﬁed  into  5  categories:  Reviews/Editorials/Letters  to  the
ditor  (REV/ED),  Epidemiology/Quality  of  Life/Psychosocial
actors  (EPI/QOL),  Diagnostic  (DX),  Treatment  (TX),  and
ranslational/Pathophysiologic  (TRANS)  studies.  In  the
esults,  the  articles  are  described  by  year,  the  country  of  the
uthors,  and  the  corresponding  categories.  The  frequency
f  the  categories  was  compared  between  Mexico  and  Latin
merica.  The  mean  number  of  articles  was  described  per
ear.  A  graph  was  plotted  with  the  number  of  articles  per
ear  to  determine  if  there  was  an  increase  in  the  publica-
ions  within  the  time  frame  of  interest,  separating  Mexico
rom  the  rest  of  Latin  America.  The  results  were  expressed
s  frequencies  and  the  comparisons  were  made  using  the
isher  exact  test.  Statistical  signiﬁcance  was  set  at  a  p  <
.05.
esults
 total  of  66  publications  from  Mexico  and  47  from  the  rest
f  Latin  America  were  identiﬁed.  Of  the  former,  57  (87.7%)
et  the  selection  criteria,  and  of  the  latter,  23  (48.9%).
able  1  shows  the  articles  according  to  the  different  cate-
ories  in  the  following  order  of  frequency:  EPI/QOL,  36.2%;
EV/ED,  27.5%;  TRANS,  18.8;  TX,  10%;  and  DX,  7.5%.  There
ere  no  differences  in  the  categories  between  Mexico  and
atin  America:  EPI/QOL,  42.1%  vs  21.3%;  REV/ED,  24.5%  vs
4.8%;  TRANS,  19.3%  vs  17.4%;  TX,  7.0%  vs  17.4%;  DX,  7.0%
s  8.7%;  p  =  0.33.
In  Mexico  approximately  3  articles/year  were  published
n  IBS,  starting  from  1997,  whereas  in  the  rest  of  Latin
merica  1.5/year  were  published  starting  from  2001.  Fur-
hermore,  in  2005,  there  was  an  increase  of  84.2%  in  the
umber  of  articles  published  in  Mexico,  reaching  a peak  in
010  (ﬁg.  1).  In  the  rest  of  Latin  America,  even  though  the
ajority  of  articles  (82.6%)  were  published  starting  from
005,  this  remained  stable  through  the  years,  with  a  peak
n  2011.  No  references  were  found  for  2014  (ﬁg.  1).
iscussion
n  the  present  review  using  the  Medline  database,  we  iden-
iﬁed  an  increase  in  publications  on  IBS  in  Mexico  and  the
est  of  Latin  America,  mainly  from  2005-2010.  Nevertheless,
t  should  be  noted  that  over  twice  as  many  articles  were
ublished  in  Mexico,  compared  with  the  other  countries  of




df Latin  America.
o  epidemiologic  aspects,  quality  of  life,  and  psychosocial
spects.
Even  though  we  identiﬁed  an  important  number  of  arti-
les  on  Medline,  it  should  be  mentioned  that  there  is  a
ublication  bias  in  that  database.  For  example,  there  are
rticles  published  in  local  journals  with  well  conducted  epi-
emiologic  studies  that  are  not  cited.  Such  is  the  case  of
 Uruguayan  study,5 as  well  as  a  Venezuelan  study,6 on  IBS
revalence.  We  also  observed  in  the  search  that  letters  to
he  editor7 and  even  recent  editorials8 on  IBS  published  in
ournals  that  are  referenced  in  Medline  were  not  identiﬁed.
herefore  in  order  to  carry  out  an  adequate  review  on  IBS
n  Mexico  and  Latin  America  it  is  necessary  to  analyze  other
atabases,  such  as  BIREME/Lilacs  or  SciELO.
With  respect  to  the  categories  of  the  articles,  it  was
ot  surprising  to  ﬁnd  that  the  majority  corresponded  to
pidemiologic  studies  and  articles  on  quality  of  life  and  psy-
hosocial  factors,  perhaps  because  they  are  the  simplest  to
onduct  and  generally  only  require  the  application  of  ques-
ionnaires.  On  the  other  hand,  grouping  these  3  aspects
nto  a single  category  can  explain  its  greater  number  of
rticles.  To  our  surprise,  the  translational  and  pathophysio-
ogic  articles  that  require  specialized  laboratory  techniques
nd  researchers,  and  that  would  have  been  thought  to  be
ess  frequent,  were  third  place  in  frequency.  This  indicates
he  ever-increasing  sophistication  of  research  in  this  ﬁeld
n  Mexico  and  Latin  America.  It  should  also  be  mentioned
hat  some  of  the  review  articles  are  collaborations  between
uthors  from  Latin  America  and  other  parts  of  the  world.9,10
his  suggests  the  growing  importance  and  leadership  at  the
nternational  level  of  certain  Latin  American  researchers  in
he  ﬁeld  of  IBS.
Finally,  the  higher  scientiﬁc  production  in  regard  to  IBS
n  Mexico  than  in  the  other  Latin  American  countries  should
lso  be  noted.  This  is  most  likely  due  to  the  fact  that
here  are  greater  funding  for  research  in  Mexico,  and  espe-
ially  the  fact  that  those  physicians  and  basic  scientists  in
cademia  are  gaining  more  recognition  and  better-paying
obs.  Such  resources  appear  to  be  scarcer  in  the  other
atin  American  countries,  and  the  effort  that  persons  in
hose  countries  must  make  to  carry  out  research  and  publish
eserves  to  be  recognized.
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Table  1  Mexican  and  Latin  American  articles  on  IBS  according  to  categories.
Article  Country  Category
Awad  RA,  Martin  J,  Guevara  M,  Ramos  R,  Noguera  JL,  Camacho  S,  Santiago  R,Ramirez
JL, Toriz  A.  Defaecography  in  patients  with  irritable  bowel  syndrome  and  healthy
volunteers.  Int  J  Colorectal  Dis.  1997;12:91-4.
Mexico  DX
Schmulson MW,  Chang  L.  Diagnostic  approach  to  the  patient  with  irritable  bowel
syndrome.  Am  J  Med.  1999;107:20S-26S.
Mexico/USA  REV/ED
Schmulson MJ.  Brain-gut  interaction  in  irritable  bowel  syndrome:  new  ﬁndings  of  a
multicomponent  disease  model.  Isr  Med  Assoc  J.  2001;3:104-10.
Mexico  REV/ED
Campos Hurtado  G,  Villareal  Menchola  J,  Cornejo  Zapata  C,  León  Barúa  R.  [Prevalence
of Manning’s  symptoms  in  a  Lima  upper  socioeconomic  level  population].  Rev
Gastroenterol  Peru.  2001;21:301-5.
Peru  EPI/QOL
Norman P.  Tegaserod  (Novartis).  IDrugs.  2002;5:171-9. UK  TX
Huerta I,  Bonder  A,  López  L,  Ocampo  MA,  Schmulson  M.  [Differences  in  the  stress
symptoms  rating  scale  in  Spanish  between  patients  with  irritable  bowel  syndrome
(IBS) and  healthy  controls].  Rev  Gastroenterol  Mex.  2002;67:161-5.
UK  EPI/QOL
Curioso WH,  Donaires  Mendoza  N,  Bacilio  Zerpa  C,  Ganoza  Gallardo  C,  León  Barúa  R.
[Prevalence  and  relation  of  dyspepsia  to  irritable  bowel  syndrome  in  a  native
community  of  the  Peruvian  jungle].  Rev  Gastroenterol  Peru.  2002;22:129-40.
Peru  EPI/QOL
Zetina-López  A,  Custodio-Vázquez  A,  Hinojosa  C,  Juárez-Paiz  L,  Schmulson  M.  [Impact
of gastrointestinal  symptoms  on  health  related  quality  of  life  in  patients  with  type  2
diabetes  mellitus].  Rev  Invest  Clin.  2003;55:594-9.
Mexico  EPI/QOL
Quera R,  Valenzuela  J.  [Visceral  hypersensitivity:  a  concept  within  our  reach].  Rev  Med
Chil. 2003;131:85-92.
Chile  REV/ED
Gómez-Escudero  O,  Schmulson-Wasserman  MJ,  Valdovinos-Díaz  MA.[Post-infectious
irritable  bowel  syndrome.  A  review  based  on  current  evidence].  Rev  Gastroenterol
Mex. 2003;68:55-61.
Mexico  REV/ED
Okhuysen PC,  Jiang  ZD,  Carlin  L,  Forbes  C,  DuPont  HL.  Post-diarrhea  chronic  intestinal
symptoms  and  irritable  bowel  syndrome  in  North  American  travelers  to  Mexico.  Am  J
Gastroenterol.  2004;99:1774-8.
USA  EPI/QOL
Sánchez RC,  Navarro  Cano  G.  [Diagnostic  value  of  limited  research  in  patients  with
irritable  bowel  syndrome].  Rev  Gastroenterol  Mex.  2004;69:24-9.
Mexico  DX
Montes R,  Monge  E.  Lactose  malabsorption  and  IBS.  Scand  J  Gastroenterol.
2004;39:1033;
Peru  REV/ED
Carmona-Sánchez  R,  Tostado-Fernández  FA.  [Prevalence  of  use  of  alternative  and
complementary  medicine  in  patients  with  irritable  bowel  syndrome,  functional
dyspepsia  and  gastroesophageal  reﬂux  disease].  Rev  Gastroenterol  Mex.
2005;70:393-8.
Mexico  TX
Cornejo Zapata  C,  Villarreal  Menchola  J.  [Relation  between  irritable  bowel  syndrome
symptoms  and  depressive  symptoms  in  hospitalized  patients].  Rev  Gastroenterol
Peru. 2005;25:156-60.
Peru  EPI/QOL
Otero Regino  W,  Gómez  Zuleta  M.  [Irritable  bowel  syndrome:  a  concise  diagnostic  and
pharmacological  therapy  review].  Rev  Gastroenterol  Peru.  2005;25:189-97.
Colombia  REV/ED
Peláez-Luna  M,  Schmulson  M,  Robles-Díaz  G.  Intestinal  involvement  is  not  sufﬁcient  to
explain hypertransaminasemia  in  celiac  disease?  Med  Hypotheses.  2005;65:937-41.
Mexico  DX
Mangel AW.  Postinfectious  IBS.  Am  J  Gastroenterol.  2005;100:729.  USA  EPI/QOL
Ariza JG,  Martínez  JA.  [Pharmacoeconomics  and  outcome  research  on  Irritable  Bowel
Syndrome  review  of  ﬁndings  using  Tegaserod].  Rev  gastroenterol  Peru.  2006;26:77-9.
Peru  TX
Leyva-Jiménez  R,  Olvera-Torres  P,  Alvarez-Córdova  MM,  Alcántar-Saldívar  EL.  [Irritable
bowel  syndrome  in  adults  attending  to  medical  ofﬁces  at  UMF].  Rev  Med  Inst  Mex
Seguro  Soc.  2006;44:473-9.
Mexico  EPI/QOL
Schmulson MJ,  Ortiz-Garrido  OM,  Hinojosa  C,  Arcila  D.  A  single  session  of  reassurance
can acutely  improve  the  self-perception  of  impairment  in  patients  with  IBS.  J
Psychosom  Res.  2006;61:461-7.
Mexico  REV/ED
Schmulson M,  Ortíz  O,  Santiago-Lomeli  M,  Gutiérrez-Reyes  G,  Gutiérrez-Ruiz  MC,
Robles-Díaz  G,  Morgan  D.  Frequency  of  functional  bowel  disorders  among  healthy
volunteers  in  Mexico  City.  Dig  Dis.  2006;2:342-7.
Mexico  EPI/QOL
Deﬁlippi G  C,  Quera  P  R,  Madrid  S  AM,  Deﬁlippi  C  C,  Valenzuela  E  J.  [Rectal  barostat  in
irritable  bowel  syndrome].  Rev  Med  Chil.  2006;134:1524-9.
Chile  DX
232  R.  Porras  et  al.
Table  1  (Continued  )
Article  Country  Category
Awad  RA,  Camacho  S,  Martín  J,  Ríos  N.  Rectal  sensation,  pelvic  ﬂoor  function  and
symptom  severity  in  Hispanic  population  with  irritable  bowel  syndrome  with
constipation.  Colorectal  Dis.  2006;8:488-93.
Mexico  EPI/QOL
Remes-Troche  JM,  Adames  K,  Castillo-Rodal  AI,  Ramírez  T,  Barreto-Zun˜iga  R,
López-Vidal  Y,  Uscanga  LF.  Intraepithelial  gammadelta+  lymphocytes:  a  comparative
study between  celiac  disease,  small  intestinal  bacterial  overgrowth,  and  irritable
bowel syndrome.  J  Clin  Gastroenterol.  2007;41:671-6.
Mexico  TRANS
Soifer LO,  Iantorno  G,  Bustos  Fernández  LM,  Soifer  G,  Dima  G,  Peralta  D,  Besasso  H.
[Breath hydrogen  levels  do  not  predict  ﬁber  intolerance  in  irritable  bowel  syndrome
with constipation].  Acta  Gastroenterol  Latinoam.  2007;37:15-9
Argentina  TX
Madrid AM,  Deﬁlippi  C  C,  Deﬁlippi  G  C,  Slimming  A  J,  Quera  P  R.  [Small  intestinal
bacterial  overgrowth  in  patients  with  functional  gastrointestinal  diseases].  Rev  Med
Chil. 2007;135:1245-52.
Chile  TRANS
Schmulson M,  Ortiz  O,  Mejia-Arangure  JM,  Hu  YB,  Morris  C,  Arcila  D,  Gutierrez-Reyes  G,
Bangdiwala  S,  Drossman  DA.  Further  validation  of  the  IBS-QOL:  female  Mexican  IBS
patients have  poorer  quality  of  life  than  females  from  North  Carolina.  Dig  Dis  Sci.
2007;52:2950-5.
Mexico  EPI/QOL
Schmulson MJ.  [Limited  diagnostic  testing  can  decrease  the  direct  economic  impact  of
irritable  bowel  syndrome].  Rev  Med  Chil.  2008;136:1398-405.
Mexico  DX
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In  conclusion,  there  has  been  an  important  increase  in
articles  on  IBS  in  Mexico  and  Latin  America  over  the  past
years,  reﬂecting  the  ever-growing  maturity  in  the  region  in
this  ﬁeld,  making  it  possible  for  us  to  have  consensuses  based
on  our  own  information.  Additionally,  in  order  to  carry  out
adequate  and  unbiased  systematic  reviews,  searches  should
also  include  local  repositories.
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